DiaMedica Therapeutics Business Summary

DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel recombinant proteins for neurological and vascular diseases with high unmet medical needs. The company’s primary business model centers on the clinical advancement and eventual commercialization or licensing of its lead product candidate, DM199 (rinvecalinase alfa), a synthetic form of the human tissue kallikrein-1 (KLK1) protein. DiaMedica currently generates revenue through strategic capital raises and private placements—most recently securing $30.1 million in July 2025—rather than product sales, as it progresses through its ReMEDy2 Phase 2/3 trial for acute ischemic stroke and Phase 2 trials for preeclampsia and fetal growth restriction. Within the competitive landscape, DiaMedica contends with players such as ZZ Biotech, BioMarin Pharmaceutical, and ACADIA Pharmaceuticals; it distinguishes itself by targeting the restoration of physiological blood flow and vascular homeostasis through a naturally occurring protein pathway rather than traditional small-molecule or device-based interventions. The leadership team is spearheaded by President and CEO Rick Pauls, who joined the board in 2005 and took the helm in 2010, bringing a venture capital pedigree from his tenure as Co-Founder of CentreStone Ventures. The executive suite includes Chief Medical Officer Dr. Julie Krop, appointed in August 2025, who previously held CMO roles at PureTech Health and Freeline Therapeutics, and Chief Financial Officer Scott Kellen, a veteran of Sun BioPharma and Kips Bay Medical. Technical operations are led by CTO Dr. Ambarish Shah, formerly of CSL Seqirus and Bristol-Myers Squibb, while commercial strategy is directed by Dominic Cundari, a 30-year Genentech veteran. The company is supported by a high-profile Board of Directors, including Chairman James Parsons and recent appointee Daniel J. O’Connor (formerly of Ambrx Biopharma), with institutional backing from notable investors such as Goldman Sachs, Geode Capital Management, and the National Research Council Canada.